Entheon Biomedical Corp.
ENTBF
$0.081
-$0.0035-4.14%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 13.32% | -32.18% | -36.85% | -65.88% | -78.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.32% | -32.18% | -36.85% | -65.88% | -79.09% |
| Operating Income | -13.32% | 32.18% | -232.89% | 28.48% | 68.34% |
| Income Before Tax | -12.99% | 33.71% | -161.89% | 21.44% | 70.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.99% | 33.71% | -161.89% | 21.44% | 70.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.99% | 33.71% | -161.89% | 21.44% | 98.76% |
| EBIT | -13.32% | 32.18% | -232.89% | 28.48% | 68.34% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.18% | 55.83% | -111.11% | 21.67% | 98.76% |
| Normalized Basic EPS | 36.76% | 54.17% | -145.83% | 31.40% | -580.00% |
| EPS Diluted | 24.18% | 64.67% | -28.38% | 21.67% | 98.76% |
| Normalized Diluted EPS | 36.76% | 54.17% | -145.83% | 31.40% | -580.00% |
| Average Basic Shares Outstanding | 49.79% | 49.92% | 23.88% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 49.79% | 49.92% | 23.88% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |